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total health care costs (p= 0.6486). ConClusions: Treatment duration was better 
among patients treated with doses above 15mg/day. Despite higher medication costs 
associated with higher doses, total health care costs were similar between the two 
groups due to lower health care resource use.
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objeCtives: To compare the psychiatric-related health care resource utilization 
and direct medical costs of schizophrenia patients initiating typical or atypical 
antipsychotics in Tianjin, China. Methods: Data were obtained from the Tianjin 
Urban Employee Basic Medical Insurance database (2008-2010). Adult schizophrenia 
patients with ≥ 1 prescription of antipsychotics after a ≥ 90-day washout period 
(during which patients didn’t receive any antipsychotics) and 12-month continu-
ous enrollment after first prescriptions were included. Psychiatric-related resource 
utilization and direct medical costs during 12-month follow-up period were esti-
mated. Chi-square test (for categorical) and two-sample t-test (for continuous) were 
conducted to detect differences between typical and atypical initiators. Logistic 
regressions controlling for demographics, mental health comorbidities, concomi-
tant medications, prior resource utilization and prior medical costs were applied to 
compare resource utilization, and ordinary least square (OLS) linear regression to 
estimate cost differences. One-to-one propensity score matching was conducted as 
a sensitivity analysis. Results: A total of 1131 patients initiated with either typical 
(N= 483) or atypical antipsychotics (N= 648). Over the 12-month follow-up, compared 
with the typical initiators, the atypical initiators had a significantly lower rate of 
hospitalization (45.8% vs. 56.7%, p< 0.001), consistent with logistic regression result 
(OR= 0.58, p< 0.001). Mean (SD) annual antipsychotic costs for the atypical initiators 
were higher than the typical initiators [$288 (431) vs. $63 (216), P< 0.001]. However, 
mean annual inpatient non-medication costs were significantly lower [atypical vs. 
typical $1213 (2061) vs. $1699 (2346), P< 0.001]. The total annual costs were not signifi-
cantly different between atypical and typical initiators [$1661 (2224) vs. $1892 (2465), 
p= 0.100], consistent with the results from OLS (atypical-typical= -$229, p= 0.091) and 
propensity score matching [$1711 (2240) vs. 1868 (2450), p= 0.341]. ConClusions: 
Although antipsychotic costs were higher for patients initiated on atypical antipsy-
chotics, atypical initiators had similar total annual direct medical costs compared to 
typical initiators, mainly due to a lower rate of atypical initiators being hospitalized.
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objeCtives: To perform a systematic review of humanistic and economic burden 
of bulimia nervosa (BN) and binge eating disorder (BED). Methods: A systematic 
literature search of English-language articles was conducted in June 2013 using 
Medline, Embase, PsycINFO, PsycARTICLES, Academic Search Complete, CINAHL 
Plus, Business Source Premier and Cochran Library. Cost data were inflated and 
converted to 2012 US$ purchasing power parities. Results: Forty-seven studies 
were included; 31 evaluated BN, 23 BED. Health-related quality of life (HRQoL) was 
reported in 29 (17 for BED), health care utilizations and/or health care costs in 
21 studies (5 for BED). Diagnoses were made using DSM-IV in 27 studies. Patient 
characteristics differed between BN and BED: for BN and BED respectively mean 
age of patients varied between 17 to 32 years and 33 to 45 years, percentage of 
female 95% to 100% and 73% to 100%, mean body mass index 20 to 24 kg/m42 and 
25 to 54 kg/m2. BN and BED greatly affected patients’ HRQoL. Compared to BN, BED 
showed lower HRQoL, although not statistically significant, in various domains of 
HRQoL (physical functioning, physical and emotional role). BN and BED appear to be 
associated with higher use of health services (hospitalization, outpatient- and emer-
gency department visits) compared to individuals without eating disorder or other 
Axis I psychiatric disorder. Average annual direct health care costs in BN and BED 
ranged from $1,160 to $9,997 and $2,923 to $4,033, respectively (in Finland, Canada, 
Germany and the United States). In BN, mean binge eating related food costs were 
$1,771 per year which was 32.7% of total food costs. ConClusions: sBN and BED 
markedly impair HRQoL. Both BN and BED are predictors of increased health care 
utilization, direct and indirect hβ ealth care costs. The limited literature warrants 
further research to better understand the humanistic and economic burden of BED.
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objeCtives: Attention-deficit/hyperactivity disorder (ADHD) is a common 
childhood psychiatric disorder, with worldwide prevalence varying from 2.2 to 
17.8%. Although stimulants are the recommended first-line treatment for ADHD, 
approximately 30% of children with ADHD do not have adequate response to the 
stimulants and may require alternative treatments to control their symptoms. 
Atomoxetine (ATX) and guanfacine extended-release (GXR) are once-daily, non-
stimulants intended for the treatment of ADHD. The objective was to assess the 
cost-effectiveness of GXR compared to ATX in the treatment of children and ado-
lescents with ADHD, from a Canadian perspective. Methods: A Markov model 
that included the following health states: treatment response, no response, and 
treatment discontinuation was developed. Transition probability from non-
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objeCtives: Buprenorphine/naloxone (BUP/NAL) combination for the treatment of 
opioid dependence is available in Film (since September 2010) and tablet formula-
tions. Earlier studies showed that treatment with film leads to better persistence 
and lower health care costs compared to BUP/NAL tablet. Higher costs were related 
to higher relapse and reinitiation rates found in the tablet treated groups. Based on 
these scientific analyses, a budget impact analysis was built to assess the health 
care expenditures related to new patients entering treatment in scenarios charac-
terized by different market shares of the two BUP/NAL formulations. Methods: 
A Markov model was structured tracking a cohort of patients initiating opioid 
dependence treatment with BUP/NAL film or BUP/NAL tablet through successive 
phases of treatment: initiation, maintenance, discontinuation, off treatment and 
reinitiation. Transition probabilities and resource utilization were estimated from 
a private insurance claims database. The total health care expenditure over five 
years was predicted for 1,000,000 lives for the following scenarios: 1) 100% market 
share BUP/NAL film formulation, 2) 100% market share BUP/NAL tablet formula-
tion broken between all BUP/NAL tablet formulations currently available in the 
market. Results: In the first year, costs of medication acquisition were found to 
be 14.4% (-US$597,244) lower in the Scenario 1. Costs of laboratory tests were 71.9% 
(US$371,547) higher. Nevertheless, this difference was outweighed by lower costs 
of outpatient care (-4.7%) (-US$88,493), inpatient psychiatric care (-51.2%) (-US$1.8 
million) and inpatient non-psychiatric care (-16.7%) (-US$703,780). Scenario 1 total 
health care costs were were19.7% (US$2.8 million) and 16.5% (US$17.2 million) lower 
in the first year and cumulatively over five years, respectively. ConClusions: 
Treatment with buprenorphine/naloxone film results in less health care resource 
utilization and lower total cost burden for private insurers when compared to treat-
ment with buprenorphine/naloxone tablet.
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objeCtives: Buprenorphine/naloxone (BUP/NAL) combination is a treatment for 
opioid dependence. The dose of BUP/NAL should be adjusted to a level that sup-
presses craving and opioid withdrawal symptoms and holds the patient in treat-
ment. The objective of this study was to estimate the impact of BUP/NAL dosing on 
treatment persistence, resource utilization and health care charges among privately 
insured patients. Methods: A retrospective cohort analysis was conducted on a 
private health insurance claims database (ClinformaticsTM DataMart) from January 
2005 to November 2012. Patients were classified in two groups based on average 
daily dose using the median as cut-off value and matched according to baseline 
characteristics. Discontinuation was defined as a gap of at least 31 days without 
prescription renewal following the theoretical end date of the previous prescrip-
tion. Resource use and related charges were calculated over the 12-month period 
after the date of treatment initiation. Results: The median of the average daily 
dose was 15.7mg/day. The matching algorithm resulted in the selection of 1,949 
patients in each group, with 64% of males, and an average age of 34 years. Patients 
in the high dose group had a 9% lower chance of discontinuation compared to 
patients treated with low dose, after adjustments (p= 0.0278). The probability of 
psychiatric hospitalization in the year following the treatment initiation was 41% 
lower in the high-dose patients (p< 0.0001) and health care charges were 23% lower 
(p= 0.0061). ConClusions: Treatment duration was longer among patients treated 
with doses above 15.7mg/day. Despite higher pharmaceutical charges, patients 
treated with higher doses had significantly lower total health care charges in the 
12 months after initiation related to lower rates of hospitalizations.
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objeCtives: Buprenorphine/naloxone (BUP/NAL) combination is a treatment for 
opioid dependence. The dose of BUP/NAL should be adjusted to a level that sup-
presses craving and opioid withdrawal symptoms and holds the patient in treat-
ment. The objective of this study was to estimate the impact of BUP/NAL dosing on 
treatment persistence, resources utilization and health care costs among Medicaid 
population. Methods: A retrospective cohort analysis was conducted on Medicaid 
insurance claims database (TruvenHealth MarketScanR Medicaid) from January 
2007 to June 2012. Patients were classified in two groups using an average daily 
dose of 15mg/day as cut-off value, and matched according to baseline characteris-
tics. Discontinuation was defined as a gap of at least 31 days without prescription 
renewal following the theoretical end date of the previous prescription. Resource 
use and related costs were calculated over the 12-month period after the date of 
treatment initiation. Results: The matching algorithm resulted in the selection of 
1,041 patients in each group, with 27% males and an average age of 34 years. Patients 
in the high dose group had an 11% lower chance of discontinuation compared to 
patients in the low dose group, after adjustments (p= 0.0377). The number of days 
of psychiatric hospitalization in the following year after treatment initiation was 
17% lower in the high dose patients (p= 0.0218) and there were no differences in 
